GlobeNewswire

GrandVision confirms HAL and EssilorLuxotica are engaged in discussions on a possible sale of controlling interest of HAL in GrandVision

Share

Schiphol, The Netherlands - 17 July 2019. GrandVision NV (Euronext: GVNV) confirms that it has been approached by EssilorLuxottica SA (Euronext: EL) and HAL Holding NV (Euronext: HAL)  in connection with a possible sale of HAL’s 76.72% ownership interest in GrandVision to EssilorLuxottica at an envisaged purchase price per share of approximately EUR28.00.

At this stage it is uncertain whether an agreement between EssilorLuxottica and HAL will be reached. While a transaction would be between HAL and EssilorLuxottica, GrandVision’s support has been requested. Completion of a sale of HAL’s ownership interest in GrandVision would be subject to customary conditions including approval from relevant regulatory authorities in various jurisdictions, which may take between 12 and 24 months. Following completion of the transaction between HAL and EssilorLuxottica, EssilorLuxottica will make a (mandatory) public offer for all shares in GrandVision.

Further announcements will be made if and when required.

This is a public announcement by GrandVision N.V. pursuant to section 17 paragraph 1 of the European Market Abuse Regulation (596/2014). This public announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities.

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Galapagos completes recruitment of NOVESA trial in systemic sclerosis5.12.2019 22:01:00 CETPress release

Mechelen, Belgium; 5 December 2019, 22.01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) has completed recruitment for the NOVESA Phase 2 clinical trial with GLPG1690. NOVESA is a double-blind, placebo-controlled Phase 2a trial evaluating the efficacy, safety and PK/PD of GLPG1690 in patients with systemic sclerosis (SSc), an autoimmune disease involving multiorgan fibrosis which has one of the highest mortality rates among rheumatic diseases1. NOVESA recruited 33 patients with diffuse cutaneous systemic sclerosis (dcSSc). One of the most visible manifestations is hardening of the skin. In dcSSc, the skin thickening is more widespread; these patients have a higher risk of developing fibrosis of multiple internal organs, including the lung. There are no approved drugs for this disease. SSc affects approximately 124,000 patients2 in the US and Europe3, with a predominance of female patients (>80%). The primary endpoint of NOVESA is the modified Rodnan Skin Score (mRSS) at 24 weeks. mRSS me

Aducanumab is good; next generation Alzheimer’s disease therapies will be better5.12.2019 18:50:00 CETPress release

New data for aducanumab strengthens potential for Alzheimer’s therapy in near term, fuels next-generation therapies with more selective binding for toxic species of amyloid beta TORONTO and CAMBRIDGE, Mass., Dec. 05, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, commends Biogen for its trailblazing efforts to advance aducanumab. Data released today at CTAD (Clinical Trials on Alzheimer’s Disease conference) strengthen aducanumab’s potential to become the first disease-modifying therapy for Alzheimer’s disease. The data clearly underscore the need for next-generation drug candidates that offer more precise binding to the misfolded beta amyloid oligomer (AßO), the toxic species of the amyloid beta protein and root cause of Alzheimer’s disease. “Today’s presentation reflects yet ano

Olainfarm invites to Third Quarter 2019 Investor Conference Webinar5.12.2019 18:17:00 CETPress release

JSC Olainfarm invites shareholders, investors, mass media representatives and other stakeholders to join its investor conference webinar scheduled on December 11, 2019 at 16:00 (EET). To join the webinar please follow the instructions below. Webinar will be hosted by the Chairman of Management Board Jeroen Weites and Investor Relations Advisor Janis Dubrovskis. The presentation will be held in English. During the webinar JSC Olainfarm representatives will inform about the recent performance of the company and financial results of third quarter and 9 months of 2019. After the presentation investors are welcome to ask questions. Due to the limited webinar time please send in your questions in advance to e-mail: ieva.unda@nasdaq.com. What is a webinar? Webinar is a virtual conference, during which company’s representative gives information about the company, its activities and future plans. Webinar allows interactive communication and provides an opportunity to ask questions and get answe

Rockridge Receives Exploration Permit for its Raney Gold Project; Planning Drilling Program in Early 20205.12.2019 14:00:00 CETPress release

VANCOUVER, British Columbia, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Rockridge Resources Ltd. (TSX-V: ROCK) (“Rockridge” or the “Company”) is pleased to announce that it has received an Exploration Permit for its Raney Gold Project located in Ontario, Canada (the “Raney Gold Project” or “Property”). The permit provides for exploration activities including geophysical surveys and diamond drilling to be conducted over a 3-year period. Highlights: Rockridge option to earn a 100% interest in the Raney Gold Project Prospective gold property located ~110 km south west of the prolific gold district of Timmins, ON Limited historical exploration campaigns conducted on the Property; the last exploration activities occurred ~10 years ago when gold prices were in the US$900/oz. range Follow-up on historical drill results, best intercept returned ~6.5 g/t gold over 8m, open for expansion Planning initial ~2,500 metre drilling program in February – April 2020; potential to discover additional gold bearing

Svensk Hypotekspension Fond 3 AB (publ) – Early redemption of notes5.12.2019 12:00:00 CETPress release

Press release 5 December 2019 Svensk Hypotekspension Fond 3 AB (publ) – Early redemption of notes Svensk Hypotekspension Fond 3 AB (publ) (the “Issuer”) informs that it intends to voluntarily redeem the SEK 2,000,000,000 Mortgage Backed Fixed Rate Notes with ISIN SE0007691621 (the “Notes”) before the first call date in accordance with the terms and conditions originally dated 6 February 2016 and as amended and restated 27 November 2019 (the “Terms and Conditions”). All outstanding Notes will be redeemed in full at their nominal amount, together with accrued but unpaid interest and an early call premium. The redemption date is expected to be 17 December 2019 (the “Redemption Date”). A notice of early redemption will today be circulated to the holders of the Notes and will be published on the website of the Issuer. The notice will be irrevocable but conditional upon the Issuer’s receipt of satisfactory evidence that the Issuer’s affiliate Svensk Hypotekspension Fond 4 AB (publ)’s notes w